



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaton  
Theodore A. Wood  
Elizabeth J. Haanes

Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhulier  
Rae Lynn P. Guest  
George S. Bardmesser  
Daniel A. Klein\*  
Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamage  
Tracy L. Muller\*  
LuAnne M. DeSantis  
Ann E. Summerfield  
Aric W. Ledford\*  
Helene C. Carlson  
Timothy A. Doyle\*  
Gaby L. Longworth  
Lori A. Gordon\*  
Nicole D. Dretar\*

Ted J. Ebersole  
Jyoti C. Iyer\*  
Laura A. Vogel  
**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Matthew J. Dowd  
Aaron L. Schwartz  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
Michelle K. Holoubek  
Robert H. DeSelms  
Simon J. Elliott

Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Michael G. Penn  
Christopher J. Walsh

**Of Counsel**  
Kenneth C. Bass III  
Evan R. Smith  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

October 12, 2004

**WRITER'S DIRECT NUMBER:**  
(202) 772-8625

**INTERNET ADDRESS:**  
ESTEPFE@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 09/458,302; Filed: December 10, 1999  
For: **Inducing Cellular Immune Responses to Carcinoembryonic Antigen  
Using Peptide and Nucleic Acid Compositions**  
Inventors: **FIKES et al.**  
Our Ref: 2060.0080005/HCC/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply to Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Exhibit 1; and
3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

EKS/PAC:dbj  
Enclosures

320688\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FIKES *et al.*

Appl. No.: 09/458,302

Filed: December 10, 1999

For: **Inducing Cellular Immune  
Responses to Carcinoembryonic  
Antigen Using Peptide and Nucleic  
Acid Compositions**

Confirmation No. 8701

Art Unit: 1644

Examiner: Ronald B. Schwadron

Atty. Docket: 2060.0080005/HCC/PAC

**Amendment and Reply to Notice to Comply with Requirements for Patent  
Application Containing Nucleotide Sequence and/or Amino Acid Sequence  
Disclosures**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated September 9, 2004, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made; and
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.